img

Global Anti-obesity Medicine Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Anti-obesity Medicine Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Anti-obesity medication or weight loss medications are pharmacological agents that reduce or control weight.
Due to the COVID-19 pandemic, the global Anti-obesity Medicine market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Prescription Drugs accounting for % of the Anti-obesity Medicine global market in 2022, is projected to value US$ million by 2034, growing at a revised % CAGR from 2024 to 2034. While Men segment is altered to an % CAGR throughout this forecast period.
The global key companies of Anti-obesity Medicine include Alizyme, Amylin Pharmaceuticals, Arena Pharmaceuticals, Boehringer Ingelheim, Eisai, GlaxoSmithKline, Orexigen Therapeutics, Vivus and Pfizer, etc. In 2022, the global top five players had a share approximately % in terms of revenue.
The United States Anti-obesity Medicine market size was US$ million in 2022, while China size was US$ million. The proportion of the United States was % in 2022, while China percentage was %, and it is predicted that China share will reach % in 2034, trailing a CAGR of % through the analysis period. As for the Europe Anti-obesity Medicine landscape, Germany is projected to reach US$ million by 2034. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Anti-obesity Medicine market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Anti-obesity Medicine market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Anti-obesity Medicine market. Readers of the report can become informed about current and future trends of the global Anti-obesity Medicine market and how they will impact market growth during the forecast period.



By Company


Alizyme
Amylin Pharmaceuticals
Arena Pharmaceuticals
Boehringer Ingelheim
Eisai
GlaxoSmithKline
Orexigen Therapeutics
Vivus
Pfizer
Roche
Merck
Novo Nordisk
Segment by Type
Prescription Drugs
OTC Drugs

Segment by Application


Men
Women
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on.
Chapter 2Revenue of Anti-obesity Medicine in global and regional level.
Chapter 3Detailed analysis of Anti-obesity Medicine companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8Asia Pacific by type, by application and by region, revenue for each segment.
Chapter 9Latin America by type, by application and by country, revenue for each segment.
Chapter 10Middle East and Africa, by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Anti-obesity Medicine revenue, gross margin, and recent development, etc.
Chapter 12Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13Research Findings and Conclusion

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Anti-obesity Medicine Market Size Growth Rate by Type: 2018 VS 2022 VS 2034
1.2.2 Prescription Drugs
1.2.3 OTC Drugs
1.3 Market by Application
1.3.1 Global Anti-obesity Medicine Market Growth Rate by Application: 2018 VS 2022 VS 2034
1.3.2 Men
1.3.3 Women
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Market Perspective
2.1 Global Anti-obesity Medicine Market Size (2018-2034)
2.2 Anti-obesity Medicine Market Size across Key Geographies Worldwide: 2018 VS 2022 VS 2034
2.3 Global Anti-obesity Medicine Market Size by Region (2018-2024)
2.4 Global Anti-obesity Medicine Market Size Forecast by Region (2024-2034)
2.5 Global Top 10 Anti-obesity Medicine Countries Ranking by Market Size
3 Anti-obesity Medicine Competitive by Company
3.1 Global Anti-obesity Medicine Revenue by Players
3.1.1 Global Anti-obesity Medicine Revenue by Players (2018-2024)
3.1.2 Global Anti-obesity Medicine Market Share by Players (2018-2024)
3.2 Global Anti-obesity Medicine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Company Covered: Ranking by Anti-obesity Medicine Revenue
3.4 Global Anti-obesity Medicine Market Concentration Ratio
3.4.1 Global Anti-obesity Medicine Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Anti-obesity Medicine Revenue in 2022
3.5 Global Key Players of Anti-obesity Medicine Head office and Area Served
3.6 Global Key Players of Anti-obesity Medicine, Product and Application
3.7 Global Key Players of Anti-obesity Medicine, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Anti-obesity Medicine Breakdown Data by Type
4.1 Global Anti-obesity Medicine Historic Revenue by Type (2018-2024)
4.2 Global Anti-obesity Medicine Forecasted Revenue by Type (2024-2034)
5 Global Anti-obesity Medicine Breakdown Data by Application
5.1 Global Anti-obesity Medicine Historic Market Size by Application (2018-2024)
5.2 Global Anti-obesity Medicine Forecasted Market Size by Application (2024-2034)
6 North America
6.1 North America Anti-obesity Medicine Revenue by Company (2021-2024)
6.2 North America Anti-obesity Medicine Revenue by Type (2018-2034)
6.3 North America Anti-obesity Medicine Revenue by Application (2018-2034)
6.4 North America Anti-obesity Medicine Revenue by Country (2018-2034)
6.4.1 United States
6.4.2 Canada
7 Europe
7.1 Europe Anti-obesity Medicine Revenue by Company (2021-2024)
7.2 Europe Anti-obesity Medicine Revenue by Type (2018-2034)
7.3 Europe Anti-obesity Medicine Revenue by Application (2018-2034)
7.4 Europe Anti-obesity Medicine Revenue by Country (2018-2034)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
8 Asia Pacific
8.1 Asia Pacific Anti-obesity Medicine Revenue by Company (2021-2024)
8.2 Asia Pacific Anti-obesity Medicine Revenue by Type (2018-2034)
8.3 Asia Pacific Anti-obesity Medicine Revenue by Application (2018-2034)
8.4 Asia Pacific Anti-obesity Medicine Revenue by Region (2018-2034)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 India
8.4.5 Australia
8.4.6 China Taiwan
8.4.7 Indonesia
8.4.8 Thailand
8.4.9 Malaysia
9 Latin America
9.1 Latin America Anti-obesity Medicine Revenue by Company (2021-2024)
9.2 Latin America Anti-obesity Medicine Revenue by Type (2018-2034)
9.3 Latin America Anti-obesity Medicine Revenue by Application (2018-2034)
9.4 Latin America Anti-obesity Medicine Revenue by Country (2018-2034)
9.4.1 Mexico
9.4.2 Brazil
9.4.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Anti-obesity Medicine Revenue by Company (2021-2024)
10.2 Middle East and Africa Anti-obesity Medicine Revenue by Type (2018-2034)
10.3 Middle East and Africa Anti-obesity Medicine Revenue by Application (2018-2034)
10.4 Middle East and Africa Anti-obesity Medicine Revenue by Country (2018-2034)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
11 Company Profiles
11.1 Alizyme
11.1.1 Alizyme Company Details
11.1.2 Alizyme Business Overview
11.1.3 Alizyme Anti-obesity Medicine Products and Services
11.1.4 Alizyme Anti-obesity Medicine Revenue in Anti-obesity Medicine Business (2018-2024)
11.1.5 Alizyme Anti-obesity Medicine SWOT Analysis
11.1.6 Alizyme Recent Development
11.2 Amylin Pharmaceuticals
11.2.1 Amylin Pharmaceuticals Company Details
11.2.2 Amylin Pharmaceuticals Business Overview
11.2.3 Amylin Pharmaceuticals Anti-obesity Medicine Products and Services
11.2.4 Amylin Pharmaceuticals Anti-obesity Medicine Revenue in Anti-obesity Medicine Business (2018-2024)
11.2.5 Amylin Pharmaceuticals Anti-obesity Medicine SWOT Analysis
11.2.6 Amylin Pharmaceuticals Recent Development
11.3 Arena Pharmaceuticals
11.3.1 Arena Pharmaceuticals Company Details
11.3.2 Arena Pharmaceuticals Business Overview
11.3.3 Arena Pharmaceuticals Anti-obesity Medicine Products and Services
11.3.4 Arena Pharmaceuticals Anti-obesity Medicine Revenue in Anti-obesity Medicine Business (2018-2024)
11.3.5 Arena Pharmaceuticals Anti-obesity Medicine SWOT Analysis
11.3.6 Arena Pharmaceuticals Recent Development
11.4 Boehringer Ingelheim
11.4.1 Boehringer Ingelheim Company Details
11.4.2 Boehringer Ingelheim Business Overview
11.4.3 Boehringer Ingelheim Anti-obesity Medicine Products and Services
11.4.4 Boehringer Ingelheim Anti-obesity Medicine Revenue in Anti-obesity Medicine Business (2018-2024)
11.4.5 Boehringer Ingelheim Anti-obesity Medicine SWOT Analysis
11.4.6 Boehringer Ingelheim Recent Development
11.5 Eisai
11.5.1 Eisai Company Details
11.5.2 Eisai Business Overview
11.5.3 Eisai Anti-obesity Medicine Products and Services
11.5.4 Eisai Anti-obesity Medicine Revenue in Anti-obesity Medicine Business (2018-2024)
11.5.5 Eisai Anti-obesity Medicine SWOT Analysis
11.5.6 Eisai Recent Development
11.6 GlaxoSmithKline
11.6.1 GlaxoSmithKline Company Details
11.6.2 GlaxoSmithKline Business Overview
11.6.3 GlaxoSmithKline Anti-obesity Medicine Products and Services
11.6.4 GlaxoSmithKline Anti-obesity Medicine Revenue in Anti-obesity Medicine Business (2018-2024)
11.6.5 GlaxoSmithKline Anti-obesity Medicine SWOT Analysis
11.6.6 GlaxoSmithKline Recent Development
11.7 Orexigen Therapeutics
11.7.1 Orexigen Therapeutics Company Details
11.7.2 Orexigen Therapeutics Business Overview
11.7.3 Orexigen Therapeutics Anti-obesity Medicine Products and Services
11.7.4 Orexigen Therapeutics Anti-obesity Medicine Revenue in Anti-obesity Medicine Business (2018-2024)
11.7.5 Orexigen Therapeutics Anti-obesity Medicine SWOT Analysis
11.7.6 Orexigen Therapeutics Recent Development
11.8 Vivus
11.8.1 Vivus Company Details
11.8.2 Vivus Business Overview
11.8.3 Vivus Anti-obesity Medicine Products and Services
11.8.4 Vivus Anti-obesity Medicine Revenue in Anti-obesity Medicine Business (2018-2024)
11.8.5 Vivus Anti-obesity Medicine SWOT Analysis
11.8.6 Vivus Recent Development
11.9 Pfizer
11.9.1 Pfizer Company Details
11.9.2 Pfizer Business Overview
11.9.3 Pfizer Anti-obesity Medicine Products and Services
11.9.4 Pfizer Anti-obesity Medicine Revenue in Anti-obesity Medicine Business (2018-2024)
11.9.5 Pfizer Anti-obesity Medicine SWOT Analysis
11.9.6 Pfizer Recent Development
11.10 Roche
11.10.1 Roche Company Details
11.10.2 Roche Business Overview
11.10.3 Roche Anti-obesity Medicine Products and Services
11.10.4 Roche Anti-obesity Medicine Revenue in Anti-obesity Medicine Business (2018-2024)
11.10.5 Roche Anti-obesity Medicine SWOT Analysis
11.10.6 Roche Recent Development
11.11 Merck
11.11.1 Merck Company Details
11.11.2 Merck Business Overview
11.11.3 Merck Anti-obesity Medicine Products and Services
11.11.4 Merck Anti-obesity Medicine Revenue in Anti-obesity Medicine Business (2018-2024)
11.11.5 Merck Recent Development
11.12 Novo Nordisk
11.12.1 Novo Nordisk Company Details
11.12.2 Novo Nordisk Business Overview
11.12.3 Novo Nordisk Anti-obesity Medicine Products and Services
11.12.4 Novo Nordisk Anti-obesity Medicine Revenue in Anti-obesity Medicine Business (2018-2024)
11.12.5 Novo Nordisk Recent Development
12 Anti-obesity Medicine Market Dynamics
12.1 Anti-obesity Medicine Industry Trends
12.2 Anti-obesity Medicine Market Drivers
12.3 Anti-obesity Medicine Market Challenges
12.4 Anti-obesity Medicine Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details

List of Figure

List of Tables
Table 1. Global Anti-obesity Medicine Market Size Growth Rate (CAGR) by Type (US$ Million), 2018 VS 2022 VS 2034
Table 2. Key Players of Prescription Drugs
Table 3. Key Players of OTC Drugs
Table 4. Global Anti-obesity Medicine Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2034
Table 5. Global Anti-obesity Medicine Market Size (US$ Million) Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2034
Table 6. Global Anti-obesity Medicine Revenue by Region (2018-2024) & (US$ Million)
Table 7. Global Anti-obesity Medicine Revenue Forecast by Region (2024-2034) & (US$ Million)
Table 8. Global Anti-obesity Medicine Market Size of Top 10 Countries, 2018 VS 2022 VS 2034, (US$ Million)
Table 9. Global Anti-obesity Medicine Revenue by Players (2018-2024) & (US$ Million)
Table 10. Global Anti-obesity Medicine Market Share by Players (2018-2024)
Table 11. Global Top Anti-obesity Medicine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-obesity Medicine as of 2022)
Table 12. Ranking of Global Top Anti-obesity Medicine Companies by Revenue (US$ Million) in 2022
Table 13. Global 5 Largest Players Market Share by Anti-obesity Medicine Revenue (CR5 and HHI) & (2018-2024)
Table 14. Global Key Players of Anti-obesity Medicine, Headquarters and Area Served
Table 15. Global Key Players of Anti-obesity Medicine, Product and Application
Table 16. Global Key Players of Anti-obesity Medicine, Date of Enter into This Industry
Table 17. Mergers & Acquisitions, Expansion Plans
Table 18. Global Anti-obesity Medicine Market Size by Type (2018-2024) & (US$ Million)
Table 19. Global Anti-obesity Medicine Revenue Market Share by Type (2018-2024)
Table 20. Global Anti-obesity Medicine Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 21. Global Anti-obesity Medicine Revenue Market Share by Type (2024-2034)
Table 22. Global Anti-obesity Medicine Market Size by Application (2018-2024) & (US$ Million)
Table 23. Global Anti-obesity Medicine Revenue Market Share by Application (2018-2024)
Table 24. Global Anti-obesity Medicine Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 25. Global Anti-obesity Medicine Revenue Market Share by Application (2024-2034)
Table 26. North America Anti-obesity Medicine Revenue by Company (2021-2024) & (US$ Million)
Table 27. North America Anti-obesity Medicine Revenue by Type (2018-2024) & (US$ Million)
Table 28. North America Anti-obesity Medicine Revenue by Type (2024-2034) & (US$ Million)
Table 29. North America Anti-obesity Medicine Revenue by Application (2018-2024) & (US$ Million)
Table 30. North America Anti-obesity Medicine Revenue by Application (2024-2034) & (US$ Million)
Table 31. North America Anti-obesity Medicine Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 32. North America Anti-obesity Medicine Revenue by Country (2018-2024) & (US$ Million)
Table 33. North America Anti-obesity Medicine Revenue by Country (2024-2034) & (US$ Million)
Table 34. Europe Anti-obesity Medicine Revenue by Company (2021-2024) & (US$ Million)
Table 35. Europe Anti-obesity Medicine Revenue by Type (2018-2024) & (US$ Million)
Table 36. Europe Anti-obesity Medicine Revenue by Type (2024-2034) & (US$ Million)
Table 37. Europe Anti-obesity Medicine Revenue by Application (2018-2024) & (US$ Million)
Table 38. Europe Anti-obesity Medicine Revenue by Application (2024-2034) & (US$ Million)
Table 39. Europe Anti-obesity Medicine Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 40. Europe Anti-obesity Medicine Revenue by Country (2018-2024) & (US$ Million)
Table 41. Europe Anti-obesity Medicine Revenue by Country (2024-2034) & (US$ Million)
Table 42. Asia Pacific Anti-obesity Medicine Revenue by Company (2021-2024) & (US$ Million)
Table 43. Asia Pacific Anti-obesity Medicine Revenue by Type (2018-2024) & (US$ Million)
Table 44. Asia Pacific Anti-obesity Medicine Revenue by Type (2024-2034) & (US$ Million)
Table 45. Asia Pacific Anti-obesity Medicine Revenue by Application (2018-2024) & (US$ Million)
Table 46. Asia Pacific Anti-obesity Medicine Revenue by Application (2024-2034) & (US$ Million)
Table 47. Asia-Pacific Anti-obesity Medicine Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2034
Table 48. Asia Pacific Anti-obesity Medicine Revenue by Region (2018-2024) & (US$ Million)
Table 49. Asia Pacific Anti-obesity Medicine Revenue by Region (2024-2034) & (US$ Million)
Table 50. Latin America Anti-obesity Medicine Revenue by Company (2021-2024) & (US$ Million)
Table 51. Latin America Anti-obesity Medicine Revenue by Type (2018-2024) & (US$ Million)
Table 52. Latin America Anti-obesity Medicine Revenue by Type (2024-2034) & (US$ Million)
Table 53. Latin America Anti-obesity Medicine Revenue by Application (2018-2024) & (US$ Million)
Table 54. Latin America Anti-obesity Medicine Revenue by Application (2024-2034) & (US$ Million)
Table 55. Latin America Anti-obesity Medicine Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 56. Latin America Anti-obesity Medicine Revenue by Country (2018-2024) & (US$ Million)
Table 57. Latin America Anti-obesity Medicine Revenue by Country (2024-2034) & (US$ Million)
Table 58. Middle East and Africa Anti-obesity Medicine Revenue by Company (2021-2024) & (US$ Million)
Table 59. Middle East and Africa Anti-obesity Medicine Revenue by Type (2018-2024) & (US$ Million)
Table 60. Middle East and Africa Anti-obesity Medicine Revenue by Type (2024-2034) & (US$ Million)
Table 61. Middle East and Africa Anti-obesity Medicine Revenue by Application (2018-2024) & (US$ Million)
Table 62. Middle East and Africa Anti-obesity Medicine Revenue by Application (2024-2034) & (US$ Million)
Table 63. Middle East and Africa Anti-obesity Medicine Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 64. Middle East and Africa Anti-obesity Medicine Revenue by Country (2018-2024) & (US$ Million)
Table 65. Middle East and Africa Anti-obesity Medicine Revenue by Country (2024-2034) & (US$ Million)
Table 66. Alizyme Company Details
Table 67. Alizyme Business Overview
Table 68. Alizyme Anti-obesity Medicine Product and Services
Table 69. Alizyme Anti-obesity Medicine Revenue in Anti-obesity Medicine Business (2018-2024) & (US$ Million)
Table 70. Alizyme Anti-obesity Medicine SWOT Analysis
Table 71. Alizyme Recent Development
Table 72. Amylin Pharmaceuticals Company Details
Table 73. Amylin Pharmaceuticals Business Overview
Table 74. Amylin Pharmaceuticals Anti-obesity Medicine Product and Services
Table 75. Amylin Pharmaceuticals Anti-obesity Medicine Revenue in Anti-obesity Medicine Business (2018-2024) & (US$ Million)
Table 76. Amylin Pharmaceuticals Anti-obesity Medicine SWOT Analysis
Table 77. Amylin Pharmaceuticals Recent Development
Table 78. Arena Pharmaceuticals Company Details
Table 79. Arena Pharmaceuticals Business Overview
Table 80. Arena Pharmaceuticals Anti-obesity Medicine Product and Services
Table 81. Arena Pharmaceuticals Anti-obesity Medicine Revenue in Anti-obesity Medicine Business (2018-2024) & (US$ Million)
Table 82. Arena Pharmaceuticals Anti-obesity Medicine SWOT Analysis
Table 83. Arena Pharmaceuticals Recent Development
Table 84. Boehringer Ingelheim Company Details
Table 85. Boehringer Ingelheim Business Overview
Table 86. Boehringer Ingelheim Anti-obesity Medicine Product and Services
Table 87. Boehringer Ingelheim Anti-obesity Medicine Revenue in Anti-obesity Medicine Business (2018-2024) & (US$ Million)
Table 88. Boehringer Ingelheim Anti-obesity Medicine SWOT Analysis
Table 89. Boehringer Ingelheim Recent Development
Table 90. Eisai Company Details
Table 91. Eisai Business Overview
Table 92. Eisai Anti-obesity Medicine Product and Services
Table 93. Eisai Anti-obesity Medicine Revenue in Anti-obesity Medicine Business (2018-2024) & (US$ Million)
Table 94. Eisai Anti-obesity Medicine SWOT Analysis
Table 95. Eisai Recent Development
Table 96. GlaxoSmithKline Company Details
Table 97. GlaxoSmithKline Business Overview
Table 98. GlaxoSmithKline Anti-obesity Medicine Product and Services
Table 99. GlaxoSmithKline Anti-obesity Medicine Revenue in Anti-obesity Medicine Business (2018-2024) & (US$ Million)
Table 100. GlaxoSmithKline Anti-obesity Medicine SWOT Analysis
Table 101. GlaxoSmithKline Recent Development
Table 102. Orexigen Therapeutics Company Details
Table 103. Orexigen Therapeutics Business Overview
Table 104. Orexigen Therapeutics Anti-obesity Medicine Product and Services
Table 105. Orexigen Therapeutics Anti-obesity Medicine Revenue in Anti-obesity Medicine Business (2018-2024) & (US$ Million)
Table 106. Orexigen Therapeutics Anti-obesity Medicine SWOT Analysis
Table 107. Orexigen Therapeutics Recent Development
Table 108. Vivus Company Details
Table 109. Vivus Business Overview
Table 110. Vivus Anti-obesity Medicine Product and Services
Table 111. Vivus Anti-obesity Medicine Revenue in Anti-obesity Medicine Business (2018-2024) & (US$ Million)
Table 112. Vivus Anti-obesity Medicine SWOT Analysis
Table 113. Vivus Recent Development
Table 114. Pfizer Company Details
Table 115. Pfizer Business Overview
Table 116. Pfizer Anti-obesity Medicine Product and Services
Table 117. Pfizer Anti-obesity Medicine Revenue in Anti-obesity Medicine Business (2018-2024) & (US$ Million)
Table 118. Pfizer Anti-obesity Medicine SWOT Analysis
Table 119. Pfizer Recent Development
Table 120. Roche Company Details
Table 121. Roche Business Overview
Table 122. Roche Anti-obesity Medicine Product and Services
Table 123. Roche Anti-obesity Medicine Revenue in Anti-obesity Medicine Business (2018-2024) & (US$ Million)
Table 124. Roche Anti-obesity Medicine SWOT Analysis
Table 125. Roche Recent Development
Table 126. Merck Company Details
Table 127. Merck Business Overview
Table 128. Merck Anti-obesity Medicine Product and Services
Table 129. Merck Anti-obesity Medicine Revenue in Anti-obesity Medicine Business (2018-2024) & (US$ Million)
Table 130. Merck Recent Development
Table 131. Novo Nordisk Company Details
Table 132. Novo Nordisk Business Overview
Table 133. Novo Nordisk Anti-obesity Medicine Product and Services
Table 134. Novo Nordisk Anti-obesity Medicine Revenue in Anti-obesity Medicine Business (2018-2024) & (US$ Million)
Table 135. Novo Nordisk Recent Development
Table 136. Anti-obesity Medicine Market Trends
Table 137. Anti-obesity Medicine Market Drivers
Table 138. Anti-obesity Medicine Market Challenges
Table 139. Anti-obesity Medicine Market Restraints
Table 140. Research Programs/Design for This Report
Table 141. Key Data Information from Secondary Sources
Table 142. Key Data Information from Primary Sources
List of Figures
Figure 1. Anti-obesity Medicine Product Picture
Figure 2. Global Anti-obesity Medicine Market Size by Type (US$ Million): 2018 VS 2022 VS 2034
Figure 3. Global Anti-obesity Medicine Market Share by Type: 2022 VS 2034
Figure 4. Prescription Drugs Features
Figure 5. OTC Drugs Features
Figure 6. Global Anti-obesity Medicine Market Size by Application (US$ Million): 2018 VS 2022 VS 2034
Figure 7. Global Anti-obesity Medicine Market Share by Application: 2022 VS 2034
Figure 8. Men
Figure 9. Women
Figure 10. Anti-obesity Medicine Report Years Considered
Figure 11. Global Anti-obesity Medicine Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 12. Global Anti-obesity Medicine Market Size 2018-2034 (US$ Million)
Figure 13. Global Anti-obesity Medicine Market Size Market Share by Region: 2022 VS 2034
Figure 14. Global Anti-obesity Medicine Revenue Market Share by Region in 2018 VS 2022
Figure 15. Global Anti-obesity Medicine Revenue Market Share Forecast by Region (2024-2034)
Figure 16. Global Top 10 Anti-obesity Medicine Countries Ranking by Market Size (US$ Million) in 2022
Figure 17. Global Anti-obesity Medicine Market Size of Top 10 Countries, 2018 VS 2022 VS 2034, (US$ Million)
Figure 18. Global Anti-obesity Medicine Market Share by Players in 2022
Figure 19. Global Top Anti-obesity Medicine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-obesity Medicine as of 2022)
Figure 20. The Top 10 and 5 Players Market Share by Anti-obesity Medicine Revenue in 2022
Figure 21. North America Anti-obesity Medicine Revenue Market Share by Company in 2022
Figure 22. North America Anti-obesity Medicine Revenue Market Share by Type (2018-2034)
Figure 23. North America Anti-obesity Medicine Revenue Market Share by Application (2018-2034)
Figure 24. North America Anti-obesity Medicine Revenue Share by Country (2018-2034)
Figure 25. United States Anti-obesity Medicine Revenue (2018-2034) & (US$ Million)
Figure 26. Canada Anti-obesity Medicine Revenue (2018-2034) & (US$ Million)
Figure 27. Europe Anti-obesity Medicine Revenue Market Share by Company in 2022
Figure 28. Europe Anti-obesity Medicine Revenue Market Share by Type (2018-2034)
Figure 29. Europe Anti-obesity Medicine Revenue Market Share by Application (2018-2034)
Figure 30. Europe Anti-obesity Medicine Revenue Share by Country (2018-2034)
Figure 31. Germany Anti-obesity Medicine Revenue (2018-2034) & (US$ Million)
Figure 32. France Anti-obesity Medicine Revenue (2018-2034) & (US$ Million)
Figure 33. U.K. Anti-obesity Medicine Revenue (2018-2034) & (US$ Million)
Figure 34. Italy Anti-obesity Medicine Revenue (2018-2034) & (US$ Million)
Figure 35. Russia Anti-obesity Medicine Revenue (2018-2034) & (US$ Million)
Figure 36. Asia Pacific Anti-obesity Medicine Revenue Market Share by Company in 2022
Figure 37. Asia Pacific Anti-obesity Medicine Revenue Market Share by Type (2018-2034)
Figure 38. Asia Pacific Anti-obesity Medicine Revenue Market Share by Application (2018-2034)
Figure 39. Asia Pacific Anti-obesity Medicine Revenue Share by Region (2018-2034)
Figure 40. China Anti-obesity Medicine Revenue (2018-2034) & (US$ Million)
Figure 41. Japan Anti-obesity Medicine Revenue (2018-2034) & (US$ Million)
Figure 42. South Korea Anti-obesity Medicine Revenue (2018-2034) & (US$ Million)
Figure 43. India Anti-obesity Medicine Revenue (2018-2034) & (US$ Million)
Figure 44. Australia Anti-obesity Medicine Revenue (2018-2034) & (US$ Million)
Figure 45. China Taiwan Anti-obesity Medicine Revenue (2018-2034) & (US$ Million)
Figure 46. Indonesia Anti-obesity Medicine Revenue (2018-2034) & (US$ Million)
Figure 47. Thailand Anti-obesity Medicine Revenue (2018-2034) & (US$ Million)
Figure 48. Malaysia Anti-obesity Medicine Revenue (2018-2034) & (US$ Million)
Figure 49. Latin America Anti-obesity Medicine Revenue Market Share by Company in 2022
Figure 50. Latin America Anti-obesity Medicine Revenue Market Share by Type (2018-2034)
Figure 51. Latin America Anti-obesity Medicine Revenue Market Share by Application (2018-2034)
Figure 52. Latin America Anti-obesity Medicine Revenue Share by Country (2018-2034)
Figure 53. Mexico Anti-obesity Medicine Revenue (2018-2034) & (US$ Million)
Figure 54. Brazil Anti-obesity Medicine Revenue (2018-2034) & (US$ Million)
Figure 55. Argentina Anti-obesity Medicine Revenue (2018-2034) & (US$ Million)
Figure 56. Middle East and Africa Anti-obesity Medicine Revenue Market Share by Company in 2022
Figure 57. Middle East and Africa Anti-obesity Medicine Revenue Market Share by Type (2018-2034)
Figure 58. Middle East and Africa Anti-obesity Medicine Revenue Market Share by Application (2018-2034)
Figure 59. Middle East and Africa Anti-obesity Medicine Revenue Share by Country (2018-2034)
Figure 60. Turkey Anti-obesity Medicine Revenue (2018-2034) & (US$ Million)
Figure 61. Saudi Arabia Anti-obesity Medicine Revenue (2018-2034) & (US$ Million)
Figure 62. UAE Anti-obesity Medicine Revenue (2018-2034) & (US$ Million)
Figure 63. Alizyme Revenue Growth Rate in Anti-obesity Medicine Business (2018-2024)
Figure 64. Amylin Pharmaceuticals Revenue Growth Rate in Anti-obesity Medicine Business (2018-2024)
Figure 65. Arena Pharmaceuticals Revenue Growth Rate in Anti-obesity Medicine Business (2018-2024)
Figure 66. Boehringer Ingelheim Revenue Growth Rate in Anti-obesity Medicine Business (2018-2024)
Figure 67. Eisai Revenue Growth Rate in Anti-obesity Medicine Business (2018-2024)
Figure 68. GlaxoSmithKline Revenue Growth Rate in Anti-obesity Medicine Business (2018-2024)
Figure 69. Orexigen Therapeutics Revenue Growth Rate in Anti-obesity Medicine Business (2018-2024)
Figure 70. Vivus Revenue Growth Rate in Anti-obesity Medicine Business (2018-2024)
Figure 71. Pfizer Revenue Growth Rate in Anti-obesity Medicine Business (2018-2024)
Figure 72. Roche Revenue Growth Rate in Anti-obesity Medicine Business (2018-2024)
Figure 73. Merck Revenue Growth Rate in Anti-obesity Medicine Business (2018-2024)
Figure 74. Novo Nordisk Revenue Growth Rate in Anti-obesity Medicine Business (2018-2024)
Figure 75. Bottom-up and Top-down Approaches for This Report
Figure 76. Data Triangulation
Figure 77. Key Executives Interviewed